{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-020465","form_type":"8-K","ticker":"APVO","cik":"0001671584","company_name":"Aptevo Therapeutics Inc.","filed_at":"2025-02-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.386602+00:00","generated_at":"2026-05-26T21:26:40.905476+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"low","headline":"Aptevo reports 100% remission in Cohort 1 of RAINIER AML trial; 59% stable disease rate in ALG.APV-527 trial","bullets":["Mipletamig RAINIER Cohort 1: 100% of patients achieved remission within 30 days, including one MRD-negative status.","ALG.APV-527 Phase 1: 59% (10/17 evaluable) stable disease rate; breast cancer patient stable >12 months.","Company expects multiple data readouts in 2025 and will present at ASH in Q4 2025.","No specific financial results for FY 2024 are disclosed in the provided exhibit text."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-020465","json":"https://secwatch.observer/filing/0000950170-25-020465.json","markdown":"https://secwatch.observer/filing/0000950170-25-020465.md","text":"https://secwatch.observer/filing/0000950170-25-020465.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1671584/000095017025020465/0000950170-25-020465-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1671584/000095017025020465/apvo-20250214.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T21:26:40.905476+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}